BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 34199132)

  • 1. Newborn Screening for Fabry Disease in Northeastern Italy: Results of Five Years of Experience.
    Gragnaniello V; Burlina AP; Polo G; Giuliani A; Salviati L; Duro G; Cazzorla C; Rubert L; Maines E; Germain DP; Burlina AB
    Biomolecules; 2021 Jun; 11(7):. PubMed ID: 34199132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of lyso-globotriaosylsphingosine in dried blood spots.
    Johnson B; Mascher H; Mascher D; Legnini E; Hung CY; Dajnoki A; Chien YH; Maródi L; Hwu WL; Bodamer OA
    Ann Lab Med; 2013 Jul; 33(4):274-8. PubMed ID: 23826564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of lyso-globotriaosylsphingosine in dried blood spots in the differential diagnosis between multiple sclerosis and Anderson-Fabry's disease.
    Olivera S; Iñiguez C; García-Fernández L; Sierra JL; Camón AM; Menao S; Torralba MÁ
    Mult Scler Relat Disord; 2020 Feb; 38():101466. PubMed ID: 31715500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive testing algorithm for the diagnosis of Fabry disease in males and females.
    Stiles AR; Zhang H; Dai J; McCaw P; Beasley J; Rehder C; Koeberl DD; McDonald M; Bali DS; Young SP
    Mol Genet Metab; 2020 Jul; 130(3):209-214. PubMed ID: 32418857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Screening Test of Fabry Disease in Patients with Renal Replacement Therapy in the City of Modena].
    Alfano G; Ganda N; Cerami C; Mori G; Fontana F; Cappelli G
    G Ital Nefrol; 2018 Mar; 35(2):. PubMed ID: 29582965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nationwide screening for Fabry disease in unselected stroke patients.
    Tomek A; Petra R; Paulasová Schwabová J; Olšerová A; Škorňa M; Nevšímalová M; Šimůnek L; Herzig R; Fafejtová Š; Mikulenka P; Táboříková A; Neumann J; Brzezny R; Sobolová H; Bartoník J; Václavík D; Vachová M; Bechyně K; Havlíková H; Prax T; Šaňák D; Černíková I; Ondečková I; Procházka P; Rajner J; Škoda M; Novák J; Škoda O; Bar M; Mikulík R; Dostálová G; Linhart A;
    PLoS One; 2021; 16(12):e0260601. PubMed ID: 34905550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of Lyso-Gb3 levels in dried blood spots and sera from patients with classic and Later-Onset Fabry disease.
    Nowak A; Mechtler T; Kasper DC; Desnick RJ
    Mol Genet Metab; 2017 Aug; 121(4):320-324. PubMed ID: 28663131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Globotriaosylsphingosine (Lyso-Gb
    Alharbi FJ; Baig S; Auray-Blais C; Boutin M; Ward DG; Wheeldon N; Steed R; Dawson C; Hughes D; Geberhiwot T
    J Inherit Metab Dis; 2018 Mar; 41(2):239-247. PubMed ID: 29294190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Ckd. Qld fabRy Epidemiology (aCQuiRE) study protocol: identifying the prevalence of Fabry disease amongst patients with kidney disease in Queensland, Australia.
    Mallett A; Kearey P; Cameron A; Healy H; Denaro C; Thomas M; Lee VW; Stark S; Fuller M; Hoy WE
    BMC Nephrol; 2020 Feb; 21(1):58. PubMed ID: 32087678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A simple method for quantification of plasma globotriaosylsphingosine: Utility for Fabry disease.
    Talbot A; Nicholls K; Fletcher JM; Fuller M
    Mol Genet Metab; 2017 Sep; 122(1-2):121-125. PubMed ID: 28847675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accuracy diagnosis improvement of Fabry disease from dried blood spots: Enzyme activity, lyso-Gb3 accumulation and GLA gene sequencing.
    Delarosa-Rodríguez R; Santotoribio JD; Paula HA; González-Meneses A; García-Morillo S; Jiménez-Arriscado P; Guerrero JM; Macher HC
    Clin Genet; 2021 Jun; 99(6):761-771. PubMed ID: 33527381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Rapid and Simple UHPLC-MS/MS Method for Quantification of Plasma Globotriaosylsphingosine (lyso-Gb3).
    Perrone A; Mohamed S; Donadio V; Liguori R; Contin M
    Molecules; 2021 Dec; 26(23):. PubMed ID: 34885938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma Globotriaosylsphingosine Level as a Primary Screening Target for Fabry Disease in Patients With Left Ventricular Hypertrophy.
    Yamashita S; Saotome M; Satoh H; Kajihara J; Mochizuki Y; Mizuno K; Nobuhara M; Miyajima K; Kumazawa A; Tominaga H; Takase H; Tawarahara K; Wakahara N; Matsunaga M; Wakabayashi Y; Matsumoto Y; Terada H; Sano M; Ohtani H; Urushida T; Hayashi H; Ishii S; Maruyama H; Maekawa Y
    Circ J; 2019 Aug; 83(9):1901-1907. PubMed ID: 31308318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma globotriaosylsphingosine as a biomarker of Fabry disease.
    Togawa T; Kodama T; Suzuki T; Sugawara K; Tsukimura T; Ohashi T; Ishige N; Suzuki K; Kitagawa T; Sakuraba H
    Mol Genet Metab; 2010 Jul; 100(3):257-61. PubMed ID: 20409739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variations in the GLA gene correlate with globotriaosylceramide and globotriaosylsphingosine analog levels in urine and plasma.
    Ferreira S; Auray-Blais C; Boutin M; Lavoie P; Nunes JP; Martins E; Garman S; Oliveira JP
    Clin Chim Acta; 2015 Jul; 447():96-104. PubMed ID: 26070511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prevalence of Fabry disease among 1009 unrelated patients with hypertrophic cardiomyopathy: a Russian nationwide screening program using NGS technology.
    Savostyanov K; Pushkov A; Zhanin I; Mazanova N; Trufanov S; Pakhomov A; Alexeeva A; Sladkov D; Asanov A; Fisenko A
    Orphanet J Rare Dis; 2022 May; 17(1):199. PubMed ID: 35578305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosing lysosomal storage disorders: Fabry disease.
    Bodamer OA; Johnson B; Dajnoki A
    Curr Protoc Hum Genet; 2013; Chapter 17():Unit17.13. PubMed ID: 23595598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Globotriaosylsphingosine (lyso-Gb
    Effraimidis G; Feldt-Rasmussen U; Rasmussen ÅK; Lavoie P; Abaoui M; Boutin M; Auray-Blais C
    J Med Genet; 2021 Oct; 58(10):692-700. PubMed ID: 32963035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients.
    Young-Gqamana B; Brignol N; Chang HH; Khanna R; Soska R; Fuller M; Sitaraman SA; Germain DP; Giugliani R; Hughes DA; Mehta A; Nicholls K; Boudes P; Lockhart DJ; Valenzano KJ; Benjamin ER
    PLoS One; 2013; 8(3):e57631. PubMed ID: 23472096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lyso-globotriaosylsphingosine (lyso-Gb3) levels in neonates and adults with the Fabry disease later-onset GLA IVS4+919G>A mutation.
    Chien YH; Bodamer OA; Chiang SC; Mascher H; Hung C; Hwu WL
    J Inherit Metab Dis; 2013 Sep; 36(5):881-5. PubMed ID: 23109060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.